NEW YORK, NY / ACCESS Newswire / July 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws.

On July 11, 2025, Capricor announced that it received a Complete Response Letter from the FDA rejecting its Biologics License Application for deramiocel, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. In the CRL, the FDA stated that the BLA "does not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data."

Following this news, CAPR's stock price fell over 38% to open at $6.99 per share on July 11, 2025. To obtain additional information, go to:

https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=156661&wire=1&utm_campaign=57

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire